Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company's proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics, Inc. is based in Plano, Texas.
Frequently asked questions
What sector does Enzolytics Inc (ENZC) operate in?
Enzolytics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Enzolytics Inc (ENZC) current stock price?
As of the latest data, Enzolytics Inc stock price is $0.00, with a previous close of $0.00. Enzolytics Inc lost -$0.00 in the last trading session, representing a -40% loss.
What is Enzolytics Inc (ENZC) current market capitalization?
Enzolytics Inc market cap is approximately 1.45 million.
What is Enzolytics Inc (ENZC) Earnings Per Share (EPS)?
The trailing EPS is -$0.43.
Does Enzolytics Inc (ENZC) pay dividends?
No. Enzolytics Inc does not pay a dividend.
What is Enzolytics Inc (ENZC) beta (volatility) score?
Enzolytics Inc has a beta of 0.739, indicating lower volatility than the overall market.